Mojito Study (Mashed Or Just Integral Pill of TicagrelOr ? )

Inclusion Criteria: * Patients presenting within 12 hours from the onset of symptoms with STEMI * Informed, written consent Exclusion Criteria: * Age \< 18 years or Age \> 75 years * Active bleeding; bleeding diathesis; coagulopathy * Increased risk of bradycardiac events * History of gastrointestinal or genitourinary bleeding \<2 months * Major surgery in the last 6 weeks * History of intracranial bleeding or structural abnormalities * Suspected aortic dissection * Any other condition that may put the patient at risk or influence study results or investigator's opinion (severe hemodynamic instability, known malignancies or other comorbid conditions with life expectancy \<1 year) * Administration in the week before the index event of clopidogrel, ticlopidine, prasugrel, ticagrelor, thrombolytics, bivalirudin, low-molecular weight heparin or fondaparinux . * Concomitant oral or IV therapy with strong CYP3A inhibitors or strong CYP3A inducers, CYP3A with narrow therapeutic windows * Known relevant hematological deviations: Hb \<10 g/dl, Thrombi. \<100x10\^9/l * Use of coumadin derivatives within the last 7 days * Chronic therapy with ticagrelor, prasugrel, clopidogrel or ticlopidine * Known severe liver disease, severe renal failure * Known allergy to the study medications * Pregnancy